Literature DB >> 6758376

On immunosurveillance in human cancer.

L Thomas.   

Abstract

The extraordinarily high incidence of cancers of many different varieties--carcinomas and lymphomas--in organ-transplant patients being maintained for long periods of time with immunosuppressive drugs is briefly reviewed. The role of immunosurveillance as a primary defense mechanism against cancer in human beings is consistent with these observations and is in need of further investigation. Conceivably, this mechanism may play a somewhat different role in humans from what has been observed in most experimental animal models.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6758376      PMCID: PMC2596448     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  10 in total

Review 1.  Immunologic approaches to the management of primary and secondary tumors involving the skin and soft tissues: review of a ten-year program.

Authors:  E Klein; O A Holtermann; F Helm; D Rosner; H Milgrom; S Adler; H L Stoll; R W Case; R L Prior; G P Murphy
Journal:  Transplant Proc       Date:  1975-06       Impact factor: 1.066

2.  Multiple primary cancers of the lung, esophagus, and other sites.

Authors:  W G Cahan
Journal:  Cancer       Date:  1977-10       Impact factor: 6.860

Review 3.  Development of cancer as a complication of clinical transplantation.

Authors:  I Penn
Journal:  Transplant Proc       Date:  1977-03       Impact factor: 1.066

4.  Non-adaptive rejection of small tumour inocula as a model of immune surveillance.

Authors:  A H Greenberg; M Greene
Journal:  Nature       Date:  1976-11-25       Impact factor: 49.962

Review 5.  Cyclosporin A.

Authors:  P J Morris
Journal:  Transplantation       Date:  1981-11       Impact factor: 4.939

6.  Kaposi's sarcoma after kidney transplantation. Report of complete remission of cutaneous and visceral involvement.

Authors:  Z Zisbrod; M Haimov; H Schanzer; E Ambinder; L Burrows
Journal:  Transplantation       Date:  1980-11       Impact factor: 4.939

7.  Reactivation of ocular malignant melanoma after renal transplantation.

Authors:  E K Spees; K K Kramer; J A Light; D D Oakes; L E Zimmerman
Journal:  Transplantation       Date:  1980-05       Impact factor: 4.939

8.  Cancer following successful cadaveric donor renal transplantation.

Authors:  A G Sheil; J F Mahony; J S Horvath; J R Johnson; D J Tiller; J H Stewart; J May
Journal:  Transplant Proc       Date:  1981-03       Impact factor: 1.066

9.  Malignant neoplasms following cardiac transplantation.

Authors:  J G Krikorian; J L Anderson; C P Bieber; I Penn; E B Stinson
Journal:  JAMA       Date:  1978-08-18       Impact factor: 56.272

10.  Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.

Authors:  R J North
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

  10 in total
  61 in total

Review 1.  A Believer's Overview of Cancer Immunosurveillance and Immunotherapy.

Authors:  Olivera J Finn
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

Review 2.  NLRC5/CITA: A Key Player in Cancer Immune Surveillance.

Authors:  Sayuri Yoshihama; Saptha Vijayan; Tabasum Sidiq; Koichi S Kobayashi
Journal:  Trends Cancer       Date:  2017-01-10

3.  Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts.

Authors:  Hiroyoshi Nishikawa; Takuma Kato; Isao Tawara; Tetsushi Takemitsu; Kanako Saito; Linan Wang; Yoshinori Ikarashi; Hiro Wakasugi; Toshinori Nakayama; Masaru Taniguchi; Kagemasa Kuribayashi; Lloyd J Old; Hiroshi Shiku
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-16       Impact factor: 11.205

Review 4.  The importance of animal models in tumor immunity and immunotherapy.

Authors:  Sadna Budhu; Jedd Wolchok; Taha Merghoub
Journal:  Curr Opin Genet Dev       Date:  2013-12-29       Impact factor: 5.578

Review 5.  Roles of the immune system in skin cancer.

Authors:  S Rangwala; K Y Tsai
Journal:  Br J Dermatol       Date:  2011-11       Impact factor: 9.302

Review 6.  NLRC5: new cancer buster?

Authors:  Feng Tang; Yadi Xu; Bing Zhao
Journal:  Mol Biol Rep       Date:  2020-01-10       Impact factor: 2.316

Review 7.  The determinants of tumour immunogenicity.

Authors:  Thomas Blankenstein; Pierre G Coulie; Eli Gilboa; Elizabeth M Jaffee
Journal:  Nat Rev Cancer       Date:  2012-03-01       Impact factor: 60.716

Review 8.  Post-transplantation malignancies: here today, gone tomorrow?

Authors:  Edward K Geissler
Journal:  Nat Rev Clin Oncol       Date:  2015-10-20       Impact factor: 66.675

Review 9.  Interferon-gamma and cancer immunoediting.

Authors:  Gavin P Dunn; Hiroaki Ikeda; Allen T Bruce; Catherine Koebel; Ravi Uppaluri; Jack Bui; Ruby Chan; Mark Diamond; J Michael White; Kathleen C F Sheehan; Robert D Schreiber
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

10.  EZH2 inhibition: a promising strategy to prevent cancer immune editing.

Authors:  Ning Kang; Mark Eccleston; Pier-Luc Clermont; Maryam Latarani; David Kingsley Male; Yuzhuo Wang; Francesco Crea
Journal:  Epigenomics       Date:  2020-09-17       Impact factor: 4.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.